A Short Cognitive and Neuropsychiatric Assessment Scale for Progressive Supranuclear Palsy

Porsche S, Klietz M, Greten S, Piot IA, Jensen I, Wegner F, Ye L, Krey L, Höllerhage M, Pötter-Nerger M, Zeitzschel M, Hagena K, Kassubek J, Patrick S, Winkler J, Berg D, Paschen S, Tönges L, Gruber D, Gandor F, Jost WH, Kühn AA, Claus I, Warnecke T, Pedrosa DJ, Eggers C, Trenkwalder C, Classen J, Schwarz J, Schnitzler A, Krause P, Schneider A, Brandt M, Falkenburger B, Zerr I, Bähr M, Weidinger E, Levin J, Katzdobler S, Düzel E, Glanz W, Teipel S, Kilimann I, Prudlo J, Gasser T, Brockmann K, Spottke A, Esser A, Petzold GC, Respondek G, Höglinger GU (2025)

Publication Type: Journal article

Publication year: 2025

Journal

DOI: 10.1002/mdc3.14348

Abstract

Background: Patients with Progressive Supranuclear Palsy (PSP) suffer from several neuropsychological impairments. These mainly affect the frontal lobe and subcortical brain structures. However, a scale for the assessment of cognitive and neuropsychiatric disability in PSP is still missing. Objectives: To create and validate a new scale for cognitive and neuropsychiatric impairment in PSP. Methods: The Short Cognitive and Neuropsychiatric (ShoCo) scale was developed containing five items (bradyphrenia, apathy, aphasia, dysexecution and disinhibition). Each item can be categorized into 0 = no deficit, 1 = mild deficit, 2 = moderate deficit and 3 = severe deficit. The total score includes 15 points, 0 meaning no deficit and 15 severe deficits. Cross-sectional and longitudinal data from 201 baseline and 71 follow up patients were analyzed. Results: Baseline ShoCo scale results were 5.9 ± 2.9. No significant differences between patients with Richardson syndrome (PSP-RS) and variants (vPSP) could be detected in the PSP-ShoCo scale scores (PSP-RS 6.1 ± 3.0, n = 160, vPSP 5.1 ± 2.6, n = 41, P = 0.057). The scale showed good correlation with established scores (eg, Montreal cognitive assessment r = −0.535, P = 0.001). The ShoCo scale showed significant annualized change within the PSP-RS patients (baseline 6.2 ± 2.9, follow up 6.9 ± 3.1, annualized diff. 1.0 ± 3.1, n = 57, P = 0.022). Conclusions: The ShoCo scale seems a promising and valid tool to measure specific neuropsychological disabilities of PSP patients in clinical routine and research.

Authors with CRIS profile

Involved external institutions

Knappschaftskrankenhaus Bottrop Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE) Paracelsus-Elena-Klinik Kassel Germany (DE) Universitätsklinikum Leipzig Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) Universitätsklinikum Münster Germany (DE) Klinikum Osnabrück Germany (DE) InnKlinikum gKU Altötting und Mühldorf Germany (DE) Heinrich-Heine-Universität Düsseldorf Germany (DE) Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) Germany (DE) Christian-Albrechts-Universität zu Kiel Germany (DE) Neurologisches Fachkrankenhaus für Bewegungsstörungen / Parkinson Germany (DE) Charité - Universitätsmedizin Berlin Germany (DE) Universität Ulm Germany (DE) Katholisches Klinikum Bochum (St. Josef- und St. Elisabeth-Hospital gGmbH) Germany (DE) Parkinson-Klinik Ortenau Germany (DE) Universitätsklinikum Gießen und Marburg (UKGM) Germany (DE)

How to cite

APA:

Porsche, S., Klietz, M., Greten, S., Piot, I.A., Jensen, I., Wegner, F.,... Höglinger, G.U. (2025). A Short Cognitive and Neuropsychiatric Assessment Scale for Progressive Supranuclear Palsy. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.14348

MLA:

Porsche, Sonja, et al. "A Short Cognitive and Neuropsychiatric Assessment Scale for Progressive Supranuclear Palsy." Movement Disorders Clinical Practice (2025).

BibTeX: Download